ArticleCancer research2020
Visualization of Activated T Cells by OX40-ImmunoPET as a Strategy for Diagnosis of Acute Graft-versus-Host Disease.
Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Trial
- Long Axial Field of View PET: A New Era of Quantitative PET Imaging for Prospective Applications Beyond Classical Theranostics.PET clinics · 2025Review
- Advancing In Vivo Detection of T-Cell Function: Development and Preclinical Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- PET-based immunomapping of intratumoral CD4Science advances · 2025Article
- Recent progress of nanomaterials for diagnosis and treatment of rejection in heart transplantation.Frontiers in bioengineering and biotechnology · 2025Review
- Ultra-low dose immunoPET usingFrontiers in medicine · 2025Article
- Validation of the C-X-C chemokine receptor 3 (CXCR3) as a target for PET imaging of T cell activation.EJNMMI research · 2024Article
- The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives.Endocrine reviews · 2024Review
- Molecular Imaging of Acute Graft-Versus-Host Disease.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Making the effect visible - OX40 targeting nanobodies forFrontiers in immunology · 2024Article
- PET assessment of acute gastrointestinal graft versus host disease.Bone marrow transplantation · 2023Review
- Noninvasive Imaging OX40Molecular imaging and biology · 2023Article
- Article
- Imaging of Activated T Cells.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Review
- Fluorophore-conjugated 4-1BB antibody enables early detection of T-cell responses in inflammatory arthritis via NIRF imaging.European journal of nuclear medicine and molecular imaging · 2022Article
- Positron Emission Tomography Probes for Imaging Cytotoxic Immune Cells.Pharmaceutics · 2022Review
- Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients.Journal for immunotherapy of cancer · 2022Review
- ICOS immunoPET enables visualization of activated T cells and early diagnosis of murine acute gastrointestinal GvHD.Blood advances · 2022Article
- Multiparameter Longitudinal Imaging of Immune Cell Activity in Chimeric Antigen Receptor T Cell and Checkpoint Blockade Therapies.ACS central science · 2022Article
- Probing immune infiltration dynamics in cancer by in vivo imaging.Current opinion in chemical biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
Graft-versus-host disease (GvHD) is a major complication of allogeneic hematopoietic cell transplantation (HCT), mediated primarily by donor T cells that become activated and attack host tissues. Noninvasive strategies detecting T-cell activation would allow for early diagnosis and possibly more effective management of HCT recipients. PET imaging is a sensitive and clinically relevant modality ideal for GvHD diagnosis, and there is a strong rationale for the use of PET tracers that can monitor T-cell activation and expansion with high specificity. The TNF receptor superfamily member OX40 (CD134) is a cell surface marker that is highly specific for activated T cells, is upregulated during GvHD, and mediates disease pathogenesis. We recently reported the development of an antibody-based activated T-cell imaging agent targeting OX40. In the present study, we visualize the dynamics of OX40 expression in an MHC-mismatch mouse model of acute GvHD using OX40-immunoPET. This approach enabled visualization of T-cell activation at early stages of disease, prior to overt clinical symptoms with high sensitivity and specificity. This study highlights the potential utility of the OX40 PET imaging as a new strategy for GvHD diagnosis and therapy monitoring. SIGNIFICANCE: OX40-immunoPET imaging is a promising noninvasive strategy for early detection of GvHD, capable of detecting signs of GvHD pathology even prior to the development of overt clinical symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.